Asia Fresh News

Asia Fresh Stories

Archive for May 19th, 2015

Jin Jiang International Hotels to Partner with 2015 China Hotel Marketing Conference

leave a comment »

SHANGHAI /PRNewswire/ — The two-day 2015 China Hotel Marketing Conference came to a successful conclusion on May 14, bringing together over 600 senior executives from the global hospitality sector who engaged in a discussion on the industry theme of “multiscreen, crossover and cross-sector”.

Mr. Simon Zhang, Chief Executive Officer of Jin Jiang International Hotel Management Co., Ltd., gives presentations at the conference (first from left)
Mr. Simon Zhang, Chief Executive Officer of Jin Jiang International Hotel Management Co., Ltd., gives presentations at the conference (first from left)

In the key CEO dialogue session held on the opening day of the conference, Mr. Simon Zhang, Chief Executive Officer of Jin Jiang International Hotels exchanged his opinions with another three business leaders on a number of topics based on their experience operating their respective hotel brands. The discussion also touched upon opportunities and challenges facing the Chinese hospitality sector, crossover and integration of the sector in the era of the internet and the impact of the emerging vacation rental model at traditional hotels.

The Chinese hospitability sector entered an era of vertical and horizontal alliances in 2014. Jin Jiang International Group acquired Louvre Group in January of 2015, an important step in the group’s global expansion strategy. Mr. Simon Zhang said, “With the acquisition, Jin Jiang further complemented the group’s hotel brand portfolio while integrating hotel resources and leveraging Louvre’s complementary regional advantages in resources, finally enhancing the group’s asset value and increased its market share.”

The theme of the conference reflects the importance of crossover and integration across the hospitality sector in the era of the internet. Jin Jiang International Hotels made significant progress in terms of crossover and integration within the company by bringing together in-house product resources and the membership system through its e-commerce business. “The company will continue to promote the crossover and integration of resources and continue its transformation into an multinational company with global reach through a comprehensive evaluation and optimization of the business, including brand consolidation, operational management, system integration and strategic development. “stated Mr. Simon Zhang. The company plans to make full use of the centralized service and management platform to improve the membership point system for brands owned by Jin Jiang and Louvre, facilitating point sharing and enhancing membership value. At the same time, the company will upgrade the guest room booking system by interconnecting the booking systems of all its hotel brands, with the aim of creating an international membership management system and a multi-layer direct sales channel network covering nearly 50 countries and regions worldwide. In addition, the company will leverage its proprietary tourism resources to launch outbound tourism services in the domestic market by working with several large Chinese tourism agencies, strengthening its cooperation with the tourism sector.

2015 marks the third consecutive year that Jin Jiang International Hotels has participated in the conference as a partner, engaging in interactions and exchanges with leading companies and business leaders across the global tourism sector as they shared leading edge industry opinions and innovative experiences. Meanwhile, facing the ever-changing and extremely competitive market, the company has continued to employ new approaches in decision-making, marketing, business processes and memorable experience in order to create a more outstanding Chinese brand.

About Jin Jiang International Hotel Management Company Ltd.

Jin Jiang International Hotel Management Company Ltd. (Jin Jiang International Hotels) has a portfolio of over 120 distinctive star rated hotels with a room inventory of over 35, 000 hotel rooms spread across 76 cities inChina. Under the Jin Jiang branding concept, the company has a new premium “J” hotel brand, five star luxury properties and four star business properties.

Jin Jiang International Holdings Company Ltd. (“Jin Jiang” or the “Group”), is China’s premier hospitality conglomerate, owner, developer and operator of hotels across all market segments. The Group manages, through its wholly owned subsidiary Jin Jiang International Hotel Management Company Ltd., the entire portfolio of owned and/or operated four and five-star hotels and its sister company Jin Jiang Inn which focuses on budget hotels. Jin Jiang International Hotels (Group) Company Ltd. is the leading operator and manager of hotels inChina. Overall, the Group owns and operates a collection of over 1,767 hotels globally, and has a total room inventory in excess of 258, 000. Amongst them, 1,339 distinctive hotels and inns are located in more than 310 cities and towns within 31 provinces, autonomous regions and municipalities across China.

Every Jin Jiang hotel is a memorable reflection of its destination’s unique style and culture. Jin Jiang International Hotels, with its qualified hotel management background and passion for excellence, dedicates itself to offering reputable hospitality services to its valued customers. With experience originating from the 1920s, its core competitiveness has accelerated in recent years. Together, the professional corporate and hotel management teams have extensive international hospitality experiences and backgrounds. This renowned company is rapidly growing and continues to strengthen and build its brand presence in China in addition to building into a strong internationally known brand.

For more information or reservations, please visit:

Photo –

Source: Jin Jiang International Hotel Management Co. Ltd.

Written by asiafreshnews

May 19, 2015 at 5:06 pm

Posted in Uncategorized

CIMA to Provide Fast Track to a Professional Accounting Qualification

leave a comment »

CIMA Signs MOA with Chulalongkorn University, Assumption University and Finn College of Business & Tourism to Deliver CIMA Qualification in Thailand

BANGKOK, May 18, 2015 /PRNewswire/ — Undergraduates pursuing an accounting degree in Chulalongkorn University and Assumption University will now be able to obtain a professional qualification in management accounting in a much shorter time. This fast track route is provided under a Memorandum of Agreement (MOA) signed between these two universities and the Chartered Institute of Management Accountants (CIMA) on 6 May 2015.

Under the agreement, these students will sit for the CIMA exam during their final year at university. Upon successful completion of this exam, they will graduate with two qualifications — an accounting degree from the university and the CIMA Diploma or Advanced Diploma in Management Accounting which are recognised by employers worldwide. They can then complete the full CIMA qualification after graduation which can be done on a part-time basis if they decide to join the workforce after graduation.

Upon completing the CIMA qualification and gaining three years of relevant work experience, they will become members of CIMA and Chartered Global Management Accountants (CGMA). CGMA is a global professional designation conferred by CIMA and the American Institute of Certified Public Accountants (AICPA).

Students in Thailand wishing to pursue the CIMA qualification can now study at the Finn College of Business & Tourism. The college is CIMA’s first tuition provider in Thailand under an MOA signed on 7 May 2015. Finn College will prepare students for the CIMA exams.

Under the 2015 syllabus, all CIMA exams are computer-based, giving students the flexibility of sitting for exams whenever they are ready. For more information, visit

Notes to Editors

The Chartered Institute of Management Accountants (CIMA), founded in 1919, is the world’s leading and largest professional body of management accountants, with over 227,000 members and students operating in 179 countries, working at the heart of business. For more information about CIMA, please visit
Source: Chartered Institute of Management Accountants (CIMA)

Written by asiafreshnews

May 19, 2015 at 4:49 pm

Posted in Uncategorized

NantWorks Acquires Cynviloq(TM) For Up To $1.3+ Billion

leave a comment »

—$90 million+ up-front payment and $1.2 billion+ milestone payments
—Sorrento retains option for co-development and/or co-marketing of Cynviloq™

SAN DIEGO/PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the NantWorks ecosystem of companies, agreed to acquire the rights to Cynviloq through the acquisition of Igdrasol, Inc., a wholly-owned subsidiary of Sorrento, which has been developing Cynviloq (paclitaxel nanoparticle polymeric micelle) in a bio-equivalence trial. Dr. Soon-Shiong was the founder of Abraxis BioScience and inventor and developer of the blockbuster drug Abraxane® (albumin-bound paclitaxel), currently approved for the treatment of breast, lung, and pancreatic cancers. Under the terms of the agreement, Sorrento will receive more than $90 million in an up-front cash payment plus the potential for more than $600 million in regulatory and $600 million in sales milestone payments. Sorrento will also receive additional transfer pricing payments from total unit sales. Furthermore, Sorrento has the option to co-develop and/or co-market Cynviloq on terms to be negotiated.

Logo –

“We are extremely pleased with the recent Cynviloq TRIBECA™ study results and excited that Dr. Patrick Soon-Shiong and his NantPharma team plan to expand Cynviloq into multiple cancer indications, as well as combine it with immunomodulatory antibodies and cell therapies from Sorrento’s pipeline,” said Dr. Henry Ji, President and CEO. “This major transaction will enhance Sorrento’s mission of bringing innovative therapies to patients in need quickly and efficiently. It puts our lead program into the hands of a team that has the experience, commitment and resources to develop and launch a major cancer drug. This transaction not only validates our prior Igdrasol acquisition, it also delivers significant financial return, while potentially offering much more in the long run to our shareholders. Moving forward, Sorrento plans to focus on truly innovative immuno-oncology and cellular therapies and position us as the leader in the emerging immunotherapy space.”

“Precision cancer medicine will require a multi-faceted treatment approach involving chemotherapy, immunotherapy, adoptive cellular therapy and next-generation precision medicine technologies, including such as genomics and proteomics diagnostics which NantWorks is developing,” said Dr. Soon-Shiong. “We are committing significant resources to the development of novel cancer therapies, including combination therapies, an area of significant unmet need. Chemotherapy is an important pillar to the combination with immunotherapy and natural killer cells, and the opportunity to develop combination regimens of low-dose metronomic use of this active drug is an important step in transforming cancer care as we know it today.”‎

About Sorrento Therapeutics, Inc.

Sorrento is an oncology company developing new treatments for cancer and associated pain.  In addition to Cynviloq, Sorrento has clinical stage asset resiniferatoxin, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain.

In December 2014, Sorrento and NantWorks formed a global joint venture, called NANTibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobile, NantMedia, NantOmics, NantBioScience, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence: to develop and deliver a diverse range of technologies that accelerates innovation, broadens the scope of scientific discovery, enhances groundbreaking research, and improves healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about whether Sorrento will receive any or all of the milestone, profit share or other payments under the agreement with NantPharma; whether Cynviloq may be approved by the FDA; and the potential for co-development or co-marketing that may be agreed pursuant to the agreement with NantPharma; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Cynviloq™, TRIBECA™, CAR.TNK™ and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their owners.

Source: Sorrento Therapeutics, Inc.

Related stocks: NASDAQ-SMALL:SRNE

Written by asiafreshnews

May 19, 2015 at 3:06 pm

Posted in Uncategorized

Boehringer Ingelheim Acquires Pharmaxis’ Phase 1 Anti-inflammatory Drug Candidate

leave a comment »

FRENCHS FOREST, Australia and INGELHEIM, Germany/PRNewswire/ — 

  • Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights.
  • PXS4728A is a highly selective oral small molecule inhibitor of vascular adhesion protein-1 that has shown activity in pre-clinical investigation in non-alcoholic steatohepatitis (NASH).
  • Drug candidate will be investigated for the treatment of NASH and has further potential in chronic obstructive pulmonary disease (COPD) and other diseases with high medical need.
  • The acquisition of this investigational anti-inflammatory drug-candidate adds a highly innovative approach to Boehringer Ingelheim’s clinical development portfolio.
  • Pharmaxis is transformed by significant deal size and recognition of its drug discovery expertise.

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences. PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor discovered by Pharmaxis that works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes. Pharmaxis has developed it through to phase 1 clinical studies, demonstrating oral bioavailability, long-lasting target inhibition and good tolerability and safety.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in Western industrialized nations. It is regarded as a major cause of fibrosis and cirrhosis of the liver and is an area of high unmet clinical need. The high prevalence of type 2 diabetes and obesity, which can lead to NASH and its long term consequences, is considered to make NASH one of the most common causes of advanced liver disorders in coming decades.

Pharmaxis CEO Mr Gary Phillips said, “This is a transformational event for Pharmaxis. With a total potential value in excess of $A750 million, it is a globally competitive deal and significant for the Australian biotech sector. We are delighted that Boehringer Ingelheim, a leader in cardiometabolic research and development, has acquired PXS4728A. Boehringer Ingelheim’s clinical expertise will now be applied to the development of this drug which has the potential to make a real difference in the treatment of diseases with high unmet clinical need.”

Glyn Parkin, Corporate SVP and Metabolism Head at Boehringer Ingelheim commented, “We have ambitious strategic goals in diabetes and metabolism and this Phase 1 asset acquisition fits well into our development portfolio. We are pleased to have achieved access to Pharmaxis’ research excellence and innovative approach to treatments for NASH. We will continue to build our portfolio through both internal and external innovation so that we are able to bring much needed medications to the patients we serve.”

Pharmaxis will receive an upfront payment of EUR27.5 million (approximately A$39m) and, subject to the continuing successful development and commercialisation of the PXS4728A program, the following payments:

  • up to a total of EUR55 million in development milestone payments tied to the commencement of phase 2 and 3 clinical trials
  • up to a total of EUR140 million in regulatory milestone payments upon filing of applications for marketing approval and receipt of regulatory and pricing approvals for a PXS4728A program product in the major pharmaceutical markets (i.e., USA, EU, and China or Japan) for the first indication
  • additional milestone payments similar in total to those set forth above upon achievement of the same development and regulatory milestone events by a PXS4728A program product for a second indication
  • earn-out payments on annual net sales of PXS4728A program products at tiered percentages starting in the high single digits
  • commercialisation milestone payments upon achievement of specified levels of annual net sales of PXS4728A program products

Boehringer will be responsible for all development, regulatory, manufacturing and commercialisation activities. Under the agreement, Boehringer has also acquired other SSAO/VAP-1 inhibitor molecules related to PXS4728A and associated patents.



Felicity Moffatt

Phone: +61-418-677-701

Boehringer Ingelheim
Dr. Reinhard Malin

Director Corporate Communications – Oncology and Pipeline
Phone: +49 (6132) 77-90815

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe andAustralia and a phase 3 trial to enable completion of an NDA for the US market is underway. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company’s development pipeline is centred around its expertise in amine oxidase chemistry and includes Semicarbazide-Sensitive Amine Oxidase Inhibitors (SSAO) for Non-alcoholic Steatohepatitis (NASH) and inflammatory diseases including Chronic Obstructive Pulmonary Disease (COPD), and Lysyl Oxidase Inhibitors (LOX) targeting fibrotic diseases including pulmonary fibrosis and some cancers. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company’s head office, research and manufacturing facilities are located in Sydney, Australia.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

About NASH

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) which is the most common liver disorder in Western industrialized nations with an estimated 30% prevalence in the United States for NAFLD and 3-5% for NASH. NASH is regarded as a major cause of cirrhosis of the liver and is an area of high unmet clinical need. The high prevalence of type 2 diabetes and obesity, which can lead to NASH and other non-alcoholic fatty liver diseases,  is expected to make NASH potentially the most common cause of advanced liver conditions in coming decades and the market has been estimated to exceed $3.5billion by 2025.

Forward-Looking Statements

Forwardlooking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of PXS4728A. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forwardlooking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.

Photo –

Source: Pharmaxis Ltd

Related stocks: Australia:PXS OTC-PINK:PXSLY

Written by asiafreshnews

May 19, 2015 at 2:41 pm

Posted in Uncategorized

German Myanmar Business Chamber Launches in Yangon

leave a comment »

-GMBC aims to be a platform of dialogue with local businesses and government

SINGAPORE  /PRNewswire/ — More than 120 business leaders and entrepreneurs attended the recent launch of the German Myanmar Business Chamber (GMBC) at the Residence of the German Ambassador, H.E. Christian-Ludwig Weber-Lortsch. The GMBC is a platform exchange between German and Myanmarcompanies that are seeking business opportunities in Southeast Asia’s fastest growing market. Furthermore, it seeks to establish a dialogue with the Myanmar government on economic frameworks.

“The GMBC will work in a spirit of partnership. In order to succeed, German and Myanmar companies need to be committed to sharing market insights, knowledge and networks with each other. The GMBC aims to foster this dynamic interaction and collaboration,” says Jens Knoke, Founding President of the GMBC. The founding Executive Committee stands exemplarily for this approach, bringing together two strong German corporates, one of the leading local manufacturers and a Joint Venture company.

With an inaugural membership of more than 50 companies, GMBC will promote German business activities withMyanmar companies and government agencies, and opportunities in Myanmar with the German business community. It will work closely with the Delegation of German Industry and Commerce to support German corporate activities while facilitating knowledge transfer towards developing the Myanmar private sector. Apart from the growing base of German companies in Myanmar, GMBC has on its roster of members Myanmarcompanies that have partnerships or are exploring opportunities with German businesses here or abroad.

Germany has a strong basis in manufacturing  a sector which needs to develop more strongly in Myanmar. While working on a strong market position in Myanmar, German member companies are committed to share know-how on efficient technologies and management. Together, we hope to build responsible and sustainable business practices that will create multiple economic opportunities and long-term progress for the country,” adds Mr. Knoke.

Germany is a long-standing partner of Myanmar. It was one of the first countries to renew and strengthen ties withMyanmar since the latter opened its doors to the international business community in 2011. Bilateral trade between the two countries has been growing steadily over the past few years. According to official German trade statistics, German exports to Myanmar reached EUR130 million in 2014. Imports have been growing dynamically to almost 100 million USD in 2014, a staggering 79% increase compared to the year before.

Germany’s main imports from Myanmar are garments, while its principal exports to Myanmar are machinery, data-processing equipment, electrical and optical goods, chemical products, motor vehicles and vehicle parts and pharmaceutical products. German companies targeting Myanmar’s growing consumer and industrial market include global leaders such as Bayer, BASF, Bosch, Henkel, Siemens and ThyssenKrupp.

About GMBC

Founded in 2015, the German Myanmar Business Chamber is the official membership organisation of companies active in German Myanmar business relations and a platform for bilateral exchange and co-operation. It works alongside the Delegation of German Industry and Commerce. Its Founding Executive Committee Members are:Jens Knoke (Henkel), Philipp Hoffmann (JJPun), Andre de Jong (Robert Bosch) and Christoph Steinwehe (Loi Hein).

For media inquiries, please contact:
Ko Ko Gyi/ Nay Lin
Mobile: +95973181337

Source: German Myanmar Business Chamber

Written by asiafreshnews

May 19, 2015 at 2:18 pm

Posted in Uncategorized Launches ‘TalentBin(R) by Monster’ in India, Gulf, Southeast Asia and Hong Kong

leave a comment »

SINGAPORE, HONG KONG and MANILA, Phillippines /PRNewswire/ —

Finding technology talent is notoriously difficult to access and recruit. Monster tried finding why.


In a skills-constrained environment, a company’s ability to find, attract, and access the right professional DNA is critical to success.

  1. Monster’s study found that the answer lies in the fact that this specialized skills talent is not always actively seeking jobs, and therefore are unlikely to have uploaded a resume to a database or created a web profile or updated in the longest time, which makes them ‘unfindable’.
  2. The conversion to hiring is bleak because recruiters are reaching the candidates who are not relevant, not knowing about the ‘unfindable’ set of professionals or they are reaching them where they don’t live as they don’t update profiles.
  3. This also prompts the need for a platform that saves recruiters time and offers a powerful pipeline and candidate tracking interface.
  4. Interestingly our survey indicates 87% agree that there is a need for disruptive technology to find this relevant talent in the right place and at the right time.

Aligning to the current situation across India, Gulf and Southeast Asia,, introduced TalentBin® by Monster. Relevant talent is not posting resumes or actively job seeking but surely is spending time online and leaving their footprints, demonstrating the professional skills that make them desirable candidates. This makes way for recruiters to find the ‘unfindable’ in time and at the right place. TalentBin® by Monster provides recruiters access to candidate profiles aggregated from social sources across the Web. Through this platform aims at finding the ‘unfindable’ talent using a storehouse of actionable information and web-based recruiting tools.

TalentBin® by Monster not only automates and streamlines the talent discovery process via automated site monitoring, interpretation and matching, but also simplifies and automates the recruiting workflow, allowing recruiters do more in less time.

By harnessing the vast amount of professionally relevant information people share across the social web, TalentBin® by Monster surfaces potential job candidates by assembling profiles using current professional activities from relevant sites. By making sense of candidate social activity, and compiling those details into a rich professional profile, complete with contact information, recruiters now can find many previously undiscoverable candidates – including those not actively seeking a new job.

For further queries please reach:
Priyanka Sharma Kaintura
Head – PR (India, Middle East, Southeast Asia, Hong Kong)


Written by asiafreshnews

May 19, 2015 at 12:40 pm

Posted in Uncategorized

USD 5 Million Prize International Robotics Challenge Announced

leave a comment »

ABU DHABI, United Arab Emirates /PRNewswire/ —

The Mohamed Bin Zayed International Robotics Challenge intends to attract the world’s best and brightest in robotics

The launch of the Mohamed Bin Zayed International Robotics Challenge (MBZIRC) was announced in a press conference at Khalifa University in Abu Dhabi, UAE on February 15, 2015. The launch event was facilitated by a robot, who directed guests to their seats. MBZIRC, organized by Abu Dhabi-based Khalifa University, will be held every two years and boasts prizes worth a total of USD 5 Million. The event is named after the Crown Prince of Abu Dhabi.


“This event will undoubtedly attract some of the best robotics minds in the world, and bring international attention to the growing robotics industry in the UAE,” said Khalifa University President, Dr. Tod Laursen. “Throughout history, challenges issued by governments, scientific communities, and international entities have often played a central role in advancing knowledge – the so-called “space race” of the 1960s is perhaps one of the most memorable examples of this idea, and the UAE has picked up this theme recently with its aspirations for a Mars mission. In a similar spirit, the MBZIRC will spur future development of worldwide robotic technology by requiring research, invention and real-life application of its winners. Challenges issued in this event will stretch participants a bit beyond the current state of the art, such that new developments and discoveries will be needed for success. We believe that a bit of audacity in challenge specification is key to the innovation process.”

The first MBZIRC will require competitors to develop aerial and ground vehicles capable of executing tasks in complex, dynamic environments. The challenge will be to create a vehicle that can complete tasks in a simulated disaster response scenario. It will involve the collaboration of a group of unmanned aerial vehicles (UAVs) and unmanned ground vehicles (UGVs) in a changing environment that requires the robots to carry out a series of tasks using autonomous navigation and environmental interactions. The challenge will be judged by an independent panel made up of international robotics experts.

Teams interested in entering the challenge can find more information at: Proposals must be submitted by June 2015, and participants will be selected in October 2015. Also, individuals can look for more information on MBZIRC on social media via #MBZIRC on Twitter and Facebook @MBZIRC.

Written by asiafreshnews

May 19, 2015 at 12:02 pm

Posted in Uncategorized

Supermicro(R) Ultra Series, TwinPro(2)(TM), FatTwin(TM) SuperServers, SuperBlade(R), SuperStorage, and 10/40GbE SDN Switches Enable Rapid Deployment of OpenStack Solutions

leave a comment »

— Industry’s Widest Range of End-to-End Server, Storage, and Networking Solutions Combined with Best-in-Class Software Partnerships Enable Complete Cloud-Scale Infrastructure Solutions

VANCOUVER, British Columbia /PRNewswire/ — Super Micro Computer, Inc. (NASDAQ: SMCI), a global leader in high-performance, high-efficiency server, storage technology and green computing, collaborates with industry leading OpenStack partners to exhibit complete compute, storage and network/controller nodes at the OpenStack Summit this week in Vancouver, Canada. The Supermicro advantage encompasses open standards-based architecture, first-to-market advanced technologies, integrated server management software, global onsite services and support and an expanding ecosystem of best-in-class open source software partners.

Photo –

“Supermicro drives next generation open source Infrastructure as a Service into enterprise, data center, and cloud environments through our extensive range of server, storage, networking and management solutions,” saidCharles Liang, President and CEO of Supermicro. “Our latest Ultra, TwinPro, FatTwin, SuperBlade, SuperStorage and top-of-rack SDN switch solutions provide the best performance, flexibility configurability and reliability required for the dynamic, highly scalable environments. With an expanding ecosystem of deployment partners and best-in-class software solutions, we are delivering total rack solutions for any scale application.”

OpenStack Infrastructure Solutions

Compute Nodes – 1U/2U/2U Ultra/2U Hyper-Speed/2U EX DP 32 DIMMs/3U MicroCloud/4U FatTwin™/7U SuperBlade® supporting quad Intel® Xeon® E7-8800/4800/2800 v2, dual Intel® Xeon® E5-2600 v3 or E3-1200 v3 CPUs, up to 24x DDR4 DIMMs up to 1.5TB, SAS3 12Gb/s, NVMe, 10GBase-T, 10G SFP+, 40G and InfiniBand Titanium Level, High-Efficiency (96%) Digital Power Supplies (SYS-1028UX-CR-LL1/-LL2, SYS-6018U-TRT+/-TRTP+/-TR4+/-TR4T+, SYS-1028U-TNRT+/-TNR4T+/-TNRTP+, SYS-1028U-TN10RT+, SYS-2028U-TRTP+, SYS-2028U-TNRT+/-TNR4T+, SYS-2028UT-BTNRT/-BC1NRT SYS-5038ML-H12TRF, SYS-5038MA-H24TRF, SYS-F618R2-FT, SBI-7228R-T2F/-T2F2/-T2X, SBI-7128RG-X/-F/-F2, SBI-7127RG/3, SBI-7126TG, SBI-7428R-T3/-T3N, SBI-7147R-S4F/-S4X)

Storage Nodes – 2U/4U 4-Node FatTwin™/4U 90x JBOD/7U SuperBlade® supporting SAS3 12Gb/s, NVMe, up to 8x 3.5″ hot-swap HDD per U (4U FatTwin), 90x 3.5″ top-load hot-swap HDDs in 4U (4U JBOD), systems support 16/24/36/72/90 drive bays (SSG-2028R-E1CR24H/24L, SSG-6038R-E1CR16N, SYS-F628R3-RTBN+/-RTBPTN+, SSG-6048R-E1CR36N, SC946ED-R2KJBOD, SBI-7128R-C6/-C6N)

Controller Nodes – 1U/2U SuperServers supporting dual Intel® Xeon® E5-2600 v3 CPUs (up to 160W TDP) up to 24x DDR4 DIMMs up to 1.5TB, SAS3 12Gb/s, NVMe, 10GBase-T, 10G SFP+, 40G and InfiniBand Titanium Level, High-Efficiency (96%) Digital Power Supplies (SYS-6017R-72RFTP+, SYS-2028U-TNRT+/-TNR4T+)

Network Nodes – 1U Short-Depth/3U MicroCloud supporting Intel® Atom™ C2758 SoC (20W, 8-core), Intel® Xeon) E5-2600 v3 or E3-1200 v3 CPUs (SYS-5018A-FTN4, SYS-5018A-MHN4, SYS-5038ML-H12TRF, SYS-5038MA-H24TRF)

Network Switches – 1U Top-of-Rack Switches in front or reverse airflow configurations supporting up to 48x 10GbE ports plus 6x 40GbE ports (SSE-X3648S/SR SDN enabled, SSE-X3848T/TR, SSE-X3848S/SR, SSE-G48-TG4, SSE-G2252, SSE-3348S/SR)

SuperRack® Solutions (SRK-42SE-02)

  • 42U-320TB (SRS-42E112-CEPH-01) – Integrated Ceph Rack, 3x Mon, 8x 2U OSD, Networking & PDU
  • 42U-1.08PB (SRS-42E136-CEPH-01) – Integrated Ceph Rack, 3x Mon, 9x 4U OSD, Networking & PDU
  • 42U-2.16PB (SRS-42E172-CEPH-01) – Integrated Ceph Rack, 3x Mon, 9x 4U OSD, Networking & PDU

Server Management Software — Supermicro Server Manager (SSM) manages wide portfolio of Supermicro servers deployed across datacenters and enables remote health monitoring, power management and firmware upgrades with a single console. SSM through automation capabilities such as REST API and CLI accelerates deployment and maintenance of servers from independent nodes to Hyperscale clusters. SSM is also packaged with Supermicro Power Manager (SPM) that can manage power on heterogeneous server vendor products and Supermicro Update Manager (SUM) that provides strong CLI interfaces for firmware upgrades.

Onsite Service and Support — Global Program Provides Rapid Hardware Maintenance Response for Supermicro Customers. Features 24 x 7 x 4 or next Business Day hardware maintenance response to Enterprise Customers with complete Supermicro SuperServer solutions. SOWs provide access to Service & Support Integration and maintenance resource augmentation.

Supermicro end-to-end hyper-converged solutions will be on exhibit at OpenStack Summit 2015 in Vancouver, Canada May 18th through the 22nd at the Vancouver Convention Centre. For more information on Supermicro’s complete range of high performance, high-efficiency Server, Storage and Networking solutions,

Follow Supermicro on Facebook and Twitter to receive their latest news and announcements.

About Super Micro Computer, Inc.

Supermicro® (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and Embedded Systems worldwide. Supermicro is committed to protecting the environment through its “We Keep IT Green®” initiative and provides customers with the most energy-efficient, environmentally-friendly solutions available on the market.

Supermicro, Building Block Solutions and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

The OpenStack® Word Mark and OpenStack Logo are either registered trademarks / service marks or trademarks / service marks of the OpenStack Foundation, in the United States and other countries and are used with the OpenStack Foundation’s permission. We are not affiliated with, endorsed or sponsored by the OpenStack Foundation or the OpenStack community

All other brands, names and trademarks are the property of their respective owners.

Photo –

Source: Super Micro Computer, Inc.

Related stocks: NASDAQ-NMS:SMCI

Written by asiafreshnews

May 19, 2015 at 11:49 am

Posted in Uncategorized